# Axitinib Before Surgery in Treating Patients With High-Risk Prostate Cancer

> **NCT01385059** · PHASE2 · COMPLETED · sponsor: **City of Hope Medical Center** · enrollment: 11 (actual)

## Conditions studied

- Stage III Prostate Cancer
- Stage IV Prostate Cancer

## Interventions

- **DRUG:** axitinib
- **PROCEDURE:** therapeutic conventional surgery
- **OTHER:** enzyme-linked immunosorbent assay
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT01385059
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10-28
- **Primary completion:** 2013-10-09
- **Final completion:** 2013-10-09
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2023-03-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01385059

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01385059, "Axitinib Before Surgery in Treating Patients With High-Risk Prostate Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01385059. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*